摘要
目的疗首发精神分裂症患者的临床疗效及安全性。方法将64例精神分裂症患者随机分为两组各32例，研究组口服阿立哌唑治疗，对照组口服利培酮治疗，观察8周。于治疗前及治疗2周、4周、6周、8周末采用阳性与阴性症状评定量表及副反应量表评定临床疗效和不良反应。结果治疗后两组阳性与阴性症状评定量表阳性症状、阴性症状因子分均较治疗前有显著下降（P均〈0．05或0．01），同期两组间评分均无显著性差异（P均〉0．05）；治疗8周末，研究组显效率65．6％，有效率84．4％，对照组分别为68．8％和87．5％，两组比较无显著性差异（P〉0．05）。两组不良反应均轻微，主要表现为嗜睡、头痛头昏、体位性低血压等；但研究组锥体外系反应、月经失调、泌乳及体重增加的发生率均显著低于对照组（P均〈0．05）。结论阿立哌唑治疗首发精神分裂症患者疗效显著且与利培酮相当，安全性高，更适合女性精神病患者。
Objective To explore the clinical efficacy and safety of aripiprazole in the treatment of first-episode schizophrenia . Methods Sixty-four schizophrenics were randomly assigned to two group of 32 patients each, research group took orally aripiprazole and con- trol group did risperidone for 8 weeks. Clinical efficaeies were assessed with the Positive and Negative Syndrome Scale （PANSS） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） before treatment and at the end of the 2nd, 4th, 6th and 8th week. Results After treatment, positive and negative symptom scores of the PANSS of both groups lowered more significantly compared with pretreatment（all P〈0.05 or 0.01）, there were no significant differences in group eomparisons（all P〉0.05）; at the end of the 8th week, the obvious effective and effective rates were 65.6% and 84.4% in the research and 68.8% and 87.5% in the control group, which showed no significant differences（P〉0.05）. Adverse reactions of both groups were mild and mainly hypersomnia, headache, dizziness, posturat hypotension and so on; incidences of extrapyramidal system reaction, menstrual disorder, lactation and weight gain were significantly lower in the research than in the control group（all P〈0. 05）. Conclusion Aripiprazole is as effective as risperidone in the treatment of first-episode schizophrenia, has higher safety and is more suitable for female mental patients.
出处
《临床心身疾病杂志》
CAS
2010年第2期127-128,共2页
Journal of Clinical Psychosomatic Diseases
